732 related articles for article (PubMed ID: 33464677)
1. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
Cariou B; Byrne CD; Loomba R; Sanyal AJ
Diabetes Obes Metab; 2021 May; 23(5):1069-1083. PubMed ID: 33464677
[TBL] [Abstract][Full Text] [Related]
2. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
5. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
Vincent RK; Williams DM; Evans M
Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
[TBL] [Abstract][Full Text] [Related]
6. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
8. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
Cariou B
Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
11. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
Belfort-DeAguiar R; Lomonaco R; Cusi K
J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
[TBL] [Abstract][Full Text] [Related]
12. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
[TBL] [Abstract][Full Text] [Related]
14. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients.
Adeghate EA
Expert Opin Pharmacother; 2024 Feb; 25(3):223-232. PubMed ID: 38458647
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review.
Lu R; Liu Y; Hong T
Diabetes Obes Metab; 2023 Apr; 25 Suppl 1():13-26. PubMed ID: 36775938
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti L; Bugianesi E; Pajvani U; Targher G
Liver Int; 2016 Nov; 36(11):1563-1579. PubMed ID: 27276701
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
